In EGFR-mutant NSCLC, ctDNA clearance during EGFR-TKI therapy is linked to improved outcomes.<h4>Methods</h4>A systematic review was conducted following PRISMA guidelines, with data from PubMed, EMBASE, Web of Science, and Cochrane Library up to September 2025. This evidence concerns the gene EGFR and non-small cell lung carcinoma.